Gossamer Bio (GOSS) Equity Average: 2022-2025
Historic Equity Average for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -$64.2 million.
- Gossamer Bio's Equity Average fell 194.67% to -$64.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.2 million, marking a year-over-year decrease of 194.67%. This contributed to the annual value of $46.1 million for FY2024, which is 23.27% up from last year.
- Per Gossamer Bio's latest filing, its Equity Average stood at -$64.2 million for Q3 2025, which was down 145.32% from -$26.2 million recorded in Q2 2025.
- In the past 5 years, Gossamer Bio's Equity Average registered a high of $83.7 million during Q4 2023, and its lowest value of -$64.2 million during Q3 2025.
- In the last 3 years, Gossamer Bio's Equity Average had a median value of $20.9 million in 2023 and averaged $16.4 million.
- Per our database at Business Quant, Gossamer Bio's Equity Average slumped by 766.20% in 2023 and then skyrocketed by 646.38% in 2024.
- Quarterly analysis of 4 years shows Gossamer Bio's Equity Average stood at $34.2 million in 2022, then surged by 144.62% to $83.7 million in 2023, then tumbled by 50.04% to $41.8 million in 2024, then crashed by 194.67% to -$64.2 million in 2025.
- Its Equity Average stands at -$64.2 million for Q3 2025, versus -$26.2 million for Q2 2025 and $11.6 million for Q1 2025.